US64132R2067 - Common Stock - Premarket: 1.45 +0.03 (+2.11%)
NASDAQ:NRBO (12/6/2022, 7:00:01 PM)-0.1 (-6.58%)
|GICS Sector||Health Care|
|Earnings (Last)||11-14 2022-11-14/bmo||Earnings (Next)||03-30 2023-03-30|
|Ins Owners||2.83%||Inst Owners||0.01%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2016-08-05. The firm is engaged in providing therapeutic programs designed to impact a range of indications in coronavirus, neurodegenerative and cardiometabolic disease. Its products include ANA001, Niclosamide, NB-01 and NB-02. The ANA001 is an oral niclosamide formulation and is being developed as a treatment for patients with moderate coronavirus disease. Niclosamide is a potential oral antiviral and anti-inflammatory agent and being studied in a 60-subject Phase II clinical trial conducted in the United States. NB-01 primarily focused on the development of a treatment for painful diabetic neuropathy (PDN). NB-02 has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition.
NEUROBO PHARMACEUTICALS INC
200 Berkeley St., Fl 19
Boston MASSACHUSETTS 02116
CEO: Richard Kang
The Center for Advancing Innovation’s Board Member, Gil Price, Realizes Turn Around in Less than 12 Months - IssueWire
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...
It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Thursday!
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
Here you can normally see the latest stock twits on NRBO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.